TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol
March 10, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022
March 04, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute
February 02, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
January 05, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial
December 27, 2021 08:00 ET
|
TRACON Pharmaceuticals, Inc.
Pre-specified Interim Analysis Concluded with Recommendation to Continue the ENVASARC Trial Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) in Each Cohort Satisfied the Bar...
TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China
November 29, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
First Approval of a Subcutaneously Administered Checkpoint Inhibitor TRACON’s Pivotal U.S. Trial for Envafolimab in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma Continues to Advance as...
TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference
November 11, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 03, 2021 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021
October 27, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors
October 13, 2021 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...